Table 1.
Current use of adjunct medications: antipsychotics, antidepressants, and other mood stabilizers
| Category | Drug | Good responders (N = 27) | Moderate/poor responders (N = 53) |
|---|---|---|---|
| Antipsychotics, N (%) | Quetiapine under 50 mg | 0 (0.0) | 4 (7.5) |
| Quetiapine over 50 mg | 5 (18.5) | 16 (30.2) | |
| Risperidone | 1 (3.7) | 8 (15.1) | |
| Olanzapine | 4 (14.8) | 5 (9.4) | |
| Ziprasidone | 0 (0.0) | 3 (5.7) | |
| Aripiprazole | 0 (0.0) | 9 (17.0) | |
| Paliperidone | 0 (0.0) | 2 (3.8) | |
| Clozapine | 1 (3.7) | 3 (5.7) | |
| Amisulpride | 1 (3.7) | 1 (1.9) | |
| Blonanserin | 1 (3.7) | 1 (1.9) | |
| Antidepressants, N (%) | Any | 0 (0.0) | 0 (0.0) |
| Other mood | Lamotrigine | 4 (14.8) | 4 (7.5) |
| Stabilizers, N (%) | Carbamazepine | 0 (0.0) | 1 (1.9) |
| Mood stabilizer polypharmacy, N (%)a | 14 (51.9) | 43 (81.1) | |
| Total number of mood stabilizers, mean (SD)a | 1.7 (0.8) | 2.2 (0.8) |
At the time of the assessment of treatment response
aIncluding index medications, atypical antipsychotics, and other mood stabilizers; for quetiapine, daily dose of 50 mg or less which is usually applied for insomnia control was excluded